Beyond intestinal soap-bile acids in metabolic control

被引:352
作者
Kuipers, Folkert [1 ]
Bloks, Vincent W. [1 ]
Groen, Albert K. [1 ]
机构
[1] Univ Groningen, Univ Med Ctr Groningen, Dept Pediat, NL-9700 RB Groningen, Netherlands
关键词
FARNESOID-X-RECEPTOR; Y GASTRIC BYPASS; FIBROBLAST GROWTH-FACTORS; TYPE-2; DIABETES-MELLITUS; ORPHAN NUCLEAR RECEPTOR; GLUCAGON-LIKE PEPTIDE-1; DIET-INDUCED OBESITY; GLYCEMIC CONTROL; ENERGY-EXPENDITURE; COLESEVELAM HYDROCHLORIDE;
D O I
10.1038/nrendo.2014.60
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Over the past decade, it has become apparent that bile acids are involved in a host of activities beyond their classic functions in bile formation and fat absorption. The identification of the farnesoid X receptor (FXR) as a nuclear receptor directly activated by bile acids and the discovery that bile acids are also ligands for the membrane-bound, G-protein coupled bile acid receptor 1 (also known as TGR5) have opened new avenues of research. Both FXR and TGR5 regulate various elements of glucose, lipid and energy metabolism. Consequently, a picture has emerged of bile acids acting as modulators of (postprandial) metabolism. Therefore, strategies that interfere with either bile acid metabolism or signalling cascades mediated by bile acids may represent novel therapeutic approaches for metabolic diseases. Synthetic modulators of FXR have been designed and tested, primarily in animal models. Furthermore, the use of bile acid sequestrants to reduce plasma cholesterol levels has unexpected benefits. For example, treatment of patients with type 2 diabetes mellitus (T2DM) with sequestrants causes substantial reductions in plasma levels of glucose and HbA(1c). This Review aims to provide an overview of the molecular mechanisms by which bile acids modulate glucose and energy metabolism, particularly focusing on the glucose-lowering actions of bile acid sequestrants in insulin resistant states and T2DM.
引用
收藏
页码:488 / 498
页数:11
相关论文
共 138 条
  • [1] The Farnesoid X Receptor Regulates Adipocyte Differentiation and Function by Promoting Peroxisome Proliferator-activated Receptor-γ and Interfering with the Wnt/β-Catenin Pathways
    Abdelkarim, Mouaadh
    Caron, Sandrine
    Duhem, Christian
    Prawitt, Janne
    Dumont, Julie
    Lucas, Anthony
    Bouchaert, Emmanuel
    Briand, Olivier
    Brozek, John
    Kuipers, Folkert
    Fievet, Catherine
    Cariou, Bertrand
    Staels, Bart
    [J]. JOURNAL OF BIOLOGICAL CHEMISTRY, 2010, 285 (47) : 36759 - 36767
  • [2] METABOLISM OF CHOLESTEROL AND PLASMA TRIGLYCERIDES IN NON-KETOTIC DIABETES-MELLITUS
    ABRAMS, JJ
    GINSBERG, H
    GRUNDY, SM
    [J]. DIABETES, 1982, 31 (10) : 903 - 910
  • [3] ALTERED BILE-ACID PROFILES IN DUODENAL BILE AND URINE IN DIABETIC SUBJECTS
    ANDERSEN, E
    KARLAGANIS, G
    SJOVALL, J
    [J]. EUROPEAN JOURNAL OF CLINICAL INVESTIGATION, 1988, 18 (02) : 166 - 172
  • [4] Circulating Fibroblast Growth Factors as Metabolic Regulators-A Critical Appraisal
    Angelin, Bo
    Larsson, Tobias E.
    Rudling, Mats
    [J]. CELL METABOLISM, 2012, 16 (06) : 693 - 705
  • [5] Host responses to the human microbiome
    Baeckhed, Fredrik
    [J]. NUTRITION REVIEWS, 2012, 70 : S14 - S17
  • [6] Barutcuoglu B, 2011, ANN CLIN LAB SCI, V41, P390
  • [7] Colesevelam hydrochloride therapy in patients with type 2 diabetes mellitus treated with metformin - Glucose and lipid effects
    Bays, Harold E.
    Goldberg, Ronald B.
    Truitt, Kenneth E.
    Jones, Michael R.
    [J]. ARCHIVES OF INTERNAL MEDICINE, 2008, 168 (18) : 1975 - 1983
  • [8] EFFECTS OF DIABETES-MELLITUS ON CHOLESTEROL-METABOLISM IN MAN
    BENNION, LJ
    GRUNDY, SM
    [J]. NEW ENGLAND JOURNAL OF MEDICINE, 1977, 296 (24) : 1365 - 1371
  • [9] Berrabah W., 2013, HEPATOLOGY
  • [10] Effect of bile acid sequestrants on glucose metabolism, hepatic de novo lipogenesis, and cholesterol and bile acid kinetics in type 2 diabetes: a randomised controlled study
    Beysen, C.
    Murphy, E. J.
    Deines, K.
    Chan, M.
    Tsang, E.
    Glass, A.
    Turner, S. M.
    Protasio, J.
    Riiff, T.
    Hellerstein, M. K.
    [J]. DIABETOLOGIA, 2012, 55 (02) : 432 - 442